Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492762 · ClinicalTrials.gov registry record · Early Phase 1
PET Imaging CCR2 in Lung Inflammation
A Early Phase 1 study of Lung Inflammation, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT03492762: Recruiting Early Phase 1 study of Lung Inflammation, sponsored by Washington University School of Medicine.
NCT03492762 is a Early Phase 1 study of Lung Inflammation that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 110 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (108% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03492762, a Early Phase 1 study of Lung Inflammation, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.
Primary Outcome
To establish the relation of lung uptake of Cu-DOTA-ECL1i compared to fibrosis determined by high resolution chest Computed tomography (CT) scan and clinical status
Conditions Studied
Interventions
- DRUG Cu-DOTA-ECL1i
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT03492762 shows while recruiting
NCT03492762 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (108% higher).
The record links to 1 condition, with Lung Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Cu-DOTA-ECL1i is the first listed.
NCT03492762 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03492762 about?
NCT03492762 is a clinical study titled "PET Imaging CCR2 in Lung Inflammation". The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiot...
What is the current status of trial NCT03492762?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 110 participants. The study started on 2018-02-27. Estimated completion is 2026-12-31.
What conditions does trial NCT03492762 study?
This clinical trial studies the following conditions: Lung Inflammation.
What interventions are being tested in trial NCT03492762?
The interventions under investigation include: Cu-DOTA-ECL1i (DRUG).
Who is sponsoring clinical trial NCT03492762?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03492762 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03492762's enrollment target sits among peer trials
110 167th of 2000 higher than 1,833 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI